Carbohydrates are well-known for their low toxicity, biocompatibility, and degradability, making them potentially useful for various delivery applications. Functionalized polysaccharides such as chitosan, hyaluronic acid, and dextran have been used to synthesize nanoparticles, hydrogels, and microspheres for targeted delivery of anti-cancer drugs, antibiotics, gene therapy, etc. Nanocarriers based on hyaluronic acid have shown selective binding to CD44 receptors overexpressed on tumor cells, which allows for targeted delivery of drugs. Moreover, their higher loading capacity tunable release kinetics, and natural origin contribute to high bioavailability and drug stability.
While the major benefits of carbohydrate-based drug delivery have been described, some technical limitations also exist that may hinder wide use. These include low loading efficiency, instability of glycosylated liposomes, and suboptimal release kinetics that affect the therapeutic efficacy and formulation stability.
Fig.1 Carbohydrates are employed in polymeric systems for drug delivery applications3,4.
Carbohydrate-based carriers, particularly polysaccharide-derived nanoparticles and hydrogels, often exhibit limited drug loading capacity due to their hydrophilic nature and lack of strong interaction sites for hydrophobic drugs. This presents a significant challenge when delivering poorly soluble or high-dose therapeutics. In many cases, physical encapsulation results in premature leakage or low entrapment efficiency, necessitating chemical modification or the incorporation of additional functional groups to enhance drug, carrier interactions. However, these modifications can increase synthesis complexity and impact reproducibility.
Glycosylation of liposomes, commonly used to improve targeting specificity and prolong circulation time, can inadvertently compromise the physical and chemical stability of the liposomal membrane. The addition of carbohydrate moieties may induce phase separation, membrane rigidity changes, or increase susceptibility to hydrolysis and oxidative degradation. Moreover, glycosylated liposomes are prone to rapid clearance by the mononuclear phagocyte system (MPS) due to recognition by carbohydrate-binding receptors, which can reduce their in vivo half-life and therapeutic window. Formulation strategies such as PEGylation or co-delivery with stabilizing agents are being explored, but they add complexity to the production process.
Controlled and site-specific drug release remains a significant hurdle for carbohydrate-based delivery systems. Many polysaccharide matrices exhibit a slow, diffusion-limited release profile, which may not align with the pharmacokinetics required for optimal therapeutic outcomes. Conversely, certain systems may release the payload too rapidly due to environmental triggers such as pH or enzymatic degradation, leading to burst release and potential off-target effects. Designing responsive systems with tunable degradation rates, stimulus-sensitivity, and sustained release behavior is critical but requires precise control over polymer chemistry, crosslinking density, and environmental interactions.
Overall, while carbohydrate-based drug delivery systems demonstrate significant potential, addressing these technical limitations is crucial to fully realize their effectiveness. Future efforts should emphasize rational design, advanced material engineering, and thorough evaluation to optimize their performance and reliability.
Table.1 Related Drug Delivery at BOC Sciences.
The advancement of carbohydrate-based drug delivery systems is hindered by several deep-rooted R&D bottlenecks. These include poor molecular design tools for glycans, the lack of scalable and reproducible synthesis methods, and the limited availability of predictive in vitro models. These fundamental limitations impact the rational design, consistent production, and accurate preclinical evaluation of glycan-based therapeutics.
Unlike proteins and nucleic acids, glycans exhibit extreme structural diversity, including variable branching patterns, linkage positions, and stereochemistry, making their molecular design and modeling highly complex. Current computational tools and structure, function prediction algorithms for glycans are significantly underdeveloped compared to those for peptides or small molecules. As a result, rational glycan engineering, whether for targeting ligands, surface modifications, or drug conjugates, remains largely empirical. This slows down the iterative optimization process in R&D and hampers the development of structure-activity relationship (SAR) models, ultimately reducing design efficiency and innovation potential.
BOC Sciences' Solution:
BOC Sciences leverages a multidisciplinary approach that integrates deep glycomics expertise, state-of-the-art in silico molecular modeling, and high-throughput screening technologies to enable rational and efficient glycan design. Our comprehensive services are tailored to meet the complex challenges of carbohydrate engineering and include:
Table.2 Molecular Design Related Services at BOC Sciences.
| Services | Inquiry |
| Drug Design Services | Inquiry |
| Formulation Services | Inquiry |
| QSAR Prediction | Inquiry |
| High-throughput Screening | Inquiry |
The synthesis of complex carbohydrates and glycan-conjugated drug carriers is notoriously difficult to scale due to challenges in regio- and stereoselective glycosidic bond formation, the need for multiple protection/deprotection steps, and batch-to-batch variability. While enzymatic and chemoenzymatic synthesis offer high specificity, they often lack scalability and require costly cofactors or specialized enzymes. Moreover, achieving reproducibility in large-scale production is complicated by the sensitivity of glycosylation reactions to environmental conditions, raw material sources, and processing parameters. These factors collectively pose significant challenges for industrial-scale manufacturing.
BOC Sciences' Solution:
BOC Sciences provides scalable glycan synthesis platforms combining chemical, enzymatic, and chemoenzymatic methods. Key features include:
Table.3 Synthesis Related Services at BOC Sciences.
| Services | Inquiry |
| Custom Synthesis | Inquiry |
| Chiral Synthesis and Resolution | Inquiry |
| Biocatalysis Services | Inquiry |
| Impurity Identification & Analysis Services | Inquiry |
| Contract Purification | Inquiry |
The evaluation of carbohydrate-based delivery systems is further constrained by the lack of physiologically relevant and predictive in vitro models. Standard 2D cell cultures often fail to replicate the complex tissue architecture, glycan-receptor expression patterns, and biological barriers encountered in vivo. This disconnect leads to poor correlation between in vitro performance and in vivo efficacy or toxicity. Furthermore, few in vitro models are tailored specifically to assess glycan-mediated interactions, such as receptor binding, immune recognition, or enzymatic degradation. The development of more advanced systems, such as 3D organoids, microfluidic "organ-on-a-chip" platforms, and glycoengineered cell lines, is essential to better predict therapeutic performance and de-risk early-stage development.
BOC Sciences' Solution:
BOC Sciences collaborates closely with leading academic institutions and industrial partners to deliver advanced assay systems that more accurately predictin vivo performance of glycan-based therapeutics. Our offerings include:
Table.4 Model Testing Related Services at BOC Sciences.
To address the critical challenges in carbohydrate-based drug delivery development, BOC Sciences offers a suite of targeted solutions designed to accelerate innovation, enhance reproducibility, and support successful translational outcomes. Backed by deep scientific expertise, BOC Sciences' services are tailored to the unique requirements of glycan-focused therapeutics, empowering researchers to overcome technical barriers and advance their R&D pipelines with confidence.
We provide end-to-end support in the rational design and synthesis of polysaccharide-based drug carriers, including nanoparticles, hydrogels, and lipo-conjugates. Leveraging a library of naturally derived and chemically modified polysaccharides (e.g., chitosan, hyaluronic acid, dextran), our team applies structure-function analysis, molecular modeling, and application-specific screening to optimize carrier properties such as drug loading capacity, targeting affinity, and release profile. Whether your goal is tumor targeting, mucosal delivery, or controlled release, we deliver customized, scalable solutions that align with your therapeutic objectives.
Table.5 Carbohydrate Conjugation Services at BOC Sciences.
| Services | Inquiry |
| Glycosylation | Inquiry |
| Glycoprotein | Inquiry |
| Carbohydrate-Oligonucleotide Conjugation | Inquiry |
| PEG Conjugated Carbohydrate | Inquiry |
| Glycolipid | Inquiry |
Recognizing the importance of formulation robustness, we offer comprehensive physicochemical and biological stability testing under simulated physiological conditions (e.g., pH variation, enzymatic degradation, serum exposure). Our analytical platforms assess parameters such as particle size stability, zeta potential, glycan integrity, and release kinetics over time. These data support rational formulation optimization and help mitigate risks during early-stage development.
Table.6 Stability Testing Services at BOC Sciences.
| Services | Inquiry |
| Thermal Analysis | Inquiry |
| Stability Studies | Inquiry |
Our team specializes in site-specific conjugation strategies for small molecules, peptides, proteins, and nucleic acids onto carbohydrate carriers, employing chemo-selective and bio-orthogonal approaches. We deliver comprehensive analytical characterization of the resulting conjugates, including assessments of purity, drug-to-carrier ratio, binding efficiency, and release profiles using HPLC, NMR, mass spectrometry, and other orthogonal techniques. These services ensure product consistency, traceability, and quality suitable for further development and application.
Through these integrated services, we empower your R&D team to overcome technical bottlenecks, accelerate time to proof-of-concept, and advance innovative carbohydrate-based delivery platforms with confidence and precision.
To explore how our tailored solutions can support your project goals, contact us for a technical consultation and customized quotation aligned with your specific development needs and timelines.
Table.7 Conjugation and Analytical Validation Services at BOC Sciences.
| Services | Inquiry |
| Structure Characterization | Inquiry |
| Purity Determination | Inquiry |
| Element Analysis | Inquiry |
| Impurity Isolation and Identification | Inquiry |
| Counter Ion Analysis | Inquiry |
Hydrophilic polysaccharide matrices lack strong interaction sites for poorly soluble therapeutics, limiting physical encapsulation efficiency. Chemical modification with hydrophobic moieties enhances drug-carrier affinity but increases synthesis complexity and batch variability.
Carbohydrate moieties can induce membrane phase separation and increased rigidity, compromising liposome physical stability. Recognition by carbohydrate-binding receptors on phagocytic cells accelerates clearance, reducing circulation half-life.
Crosslinking density controls diffusion-limited release rates, with tighter networks slowing payload efflux. pH-sensitive or enzyme-degradable linkers enable triggered release in response to specific microenvironmental cues.
Molecular modeling platforms predict glycan-receptor interactions for CD44 and mannose receptor targeting. Structure-activity relationship analysis guides optimization of ligand affinity and selectivity for specific biological contexts.
Chemoenzymatic approaches combine chemical glycosylation with enzymatic extension for complex oligosaccharide assembly. Optimized purification workflows using HPLC ensure batch-to-batch consistency for industrial-scale manufacturing.
3D spheroid cultures recapitulate tissue architecture and barrier properties for penetration studies. Glycoengineered cell lines expressing defined receptor profiles enable precise evaluation of targeted uptake mechanisms.
HA selectively binds CD44 receptors overexpressed on various tumor cell surfaces for active targeting. Nanoparticle internalization via receptor-mediated endocytosis enhances intracellular drug accumulation in malignant tissues.
High-resolution mass spectrometry confirms molecular weight and conjugation site specificity. HPLC quantifies drug-to-carrier ratios while NMR spectroscopy verifies glycan structural integrity post-conjugation.
References
